SC
OCUL icon

Stephens Consulting’s Ocular Therapeutix OCUL Stock Holding History

Stephens Consulting’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50
Closed -$367 – 1729
2025
Q1 		$367 Buy
+50
New +$384 ﹤0.01% 1224
2023
Q4 		– Sell
-4,000
Closed -$12.6K – 500
2023
Q3 		$12.6K Buy
+4,000
New +$16.4K 0.01% 291

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Stephens Consulting's OCUL Position: Q2 2025 in Review

Stephens Consulting sold out of Ocular Therapeutix (OCUL) in Q2 2025, closing a stake of 50 shares — an estimated $367 sold.

Stephens Consulting first reported a position in OCUL in Q3 2023 and held it in 2 quarters. The position peaked at $12.6K in Q3 2023. 186 funds tracked by Wall St. Rank hold OCUL as of Q2 2025.

  • Stephens Consulting reported no remaining Ocular Therapeutix position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 50 Ocular Therapeutix shares in Q2 2025, an estimated $367.
  • Stephens Consulting first reported a position in Ocular Therapeutix in Q3 2023 and held it in 2 quarters.
  • Stephens Consulting's Ocular Therapeutix position peaked at $12.6K in Q3 2023.
  • 186 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.